Arbeitsgruppe CUP-Syndrom - Studien
| CUP – palliative Therapie, 1st-line | ||||
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-CUP-0117/ass: A Phase II, Active-Controlled, Multicenter Study Comparing The Efficacy & Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling vs. Platinum Based Chemotherapy in Patients with Cancer of Unknown Primary Site who Have Received Three Cylcles of Platinum Doublet Chemotherapy, MX39795 (CUPISCO) |
||||
| ---in Rekrutierung --- | ||||
| CUP palliative Therapie - 2nd-line | ||||
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-CUP-0119/ass: A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy (CheCUP) | ||||
| ---in Rekrutierung --- | ||||
| LETZTE AKTUALISIERUNG DIESER SEITE AM: 08.12.2019 |